Soliris

Soliris, also known by its generic name eculizumab, is a medication used to treat certain rare and serious conditions. It is a monoclonal antibody that targets the complement system, a part of the immune system. Specifically, Soliris inhibits the cleavage of complement protein C5, thereby preventing the formation of the membrane attack complex (MAC), which can damage cells.

The primary indications for Soliris are paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). In PNH, the complement system inappropriately attacks red blood cells, leading to anemia, blood clots, and other complications. Soliris helps to prevent this destruction of red blood cells. In aHUS, uncontrolled activation of the complement system leads to blood clots in small blood vessels, particularly in the kidneys, which can cause kidney failure. Soliris is also approved for treating generalized myasthenia gravis (gMG) in adults who are anti-acetylcholine receptor antibody-positive, and for neuromyelitis optica spectrum disorder (NMOSD) in adults who are anti-aquaporin-4 antibody-positive.

Soliris is administered intravenously by a healthcare professional. Due to its mechanism of action, Soliris can increase the risk of meningococcal infections. Therefore, patients receiving Soliris must be vaccinated against Neisseria meningitidis before starting treatment and remain up-to-date with vaccinations. Other potential side effects include headache, nausea, and infections. It is a significant advancement in the treatment of these previously life-threatening diseases.